이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Cannara Biotech 대차 대조표 상태

재무 상태 기준 확인 3/6

Cannara Biotech 의 총 주주 지분은 CA$79.3M 이고 총 부채는 CA$48.7M, 이는 부채 대 자기자본 비율을 61.4% 로 가져옵니다. 총자산과 총부채는 각각 CA$145.8M 및 CA$66.5M 입니다. Cannara Biotech 의 EBIT는 CA$11.5M 이며 이자보상배율은 2.5 입니다. CA$3.1M 의 현금 및 단기 투자금을 보유하고 있습니다.

주요 정보

58.9%

부채 비율

CA$48.17m

부채

이자 보상 비율	1.7x
현금	CA$5.46m
주식	CA$81.77m
총 부채	CA$67.00m
총 자산	CA$148.77m

최근 재무 상태 업데이트

Recent updates

Does Cannara Biotech (CVE:LOVE) Have A Healthy Balance Sheet?

Jul 14

Cannara Biotech Inc.'s (CVE:LOVE) Prospects Need A Boost To Lift Shares

May 09

Here's Why We Think Cannara Biotech (CVE:LOVE) Might Deserve Your Attention Today

Feb 28

Investor Optimism Abounds Cannara Biotech Inc. (CVE:LOVE) But Growth Is Lacking

Jan 24

Cannara Biotech's (CVE:LOVE) Earnings May Just Be The Starting Point

Dec 18

Is Cannara Biotech (CVE:LOVE) A Risky Investment?

Jul 29

Cannara Biotech Inc.'s (CVE:LOVE) Business Is Yet to Catch Up With Its Share Price

Apr 10

Here's Why Cannara Biotech (CVE:LOVE) Has A Meaningful Debt Burden

Jan 26

Cannara Biotech's (CVE:LOVE) Earnings Aren't As Good As They Appear

Jan 27

Cannara Biotech (CVE:LOVE) Has A Somewhat Strained Balance Sheet

Dec 10

Here's Why Cannara Biotech (CSE:LOVE) Can Afford Some Debt

Mar 16

Can You Imagine How Cannara Biotech's (CSE:LOVE) Shareholders Feel About The -6.5% Share Price Increase?

Jan 22

Have Insiders Been Buying Cannara Biotech Inc. (CSE:LOVE) Shares?

Dec 18

재무 상태 분석

단기부채: LOVE 의 단기 자산 ( CA$62.0M )이 단기 부채( CA$26.8M ).

장기 부채: LOVE 의 단기 자산( CA$58.2M )이 장기 부채( CA$6.4M ).

부채 대 자본 내역 및 분석

부채 수준: LOVE 의 순부채 대 자기자본 비율( 57.4% )은 높음으로 간주됩니다.

부채 감소: LOVE 의 부채 대 자기자본 비율은 지난 5년간 38.9% 에서 61.4% 로 증가했습니다.

부채 범위: LOVE 의 부채는 영업 현금 흐름 ( 21.5% )에 의해 잘 충당되었습니다.

이자 보장: LOVE 의 부채에 대한 이자 지급은 EBIT( 2.5 x 적용 범위)만큼 잘 덮이지 않음입니다.

Cannara Biotech 대차 대조표 상태

재무 상태 기준 확인 3/6

주요 정보

최근 재무 상태 업데이트

Does Cannara Biotech (CVE:LOVE) Have A Healthy Balance Sheet?

Is Cannara Biotech (CVE:LOVE) A Risky Investment?

Here's Why Cannara Biotech (CVE:LOVE) Has A Meaningful Debt Burden

Cannara Biotech (CVE:LOVE) Has A Somewhat Strained Balance Sheet

Here's Why Cannara Biotech (CSE:LOVE) Can Afford Some Debt

Recent updates

Third quarter 2024 earnings released: EPS: CA$0.022 (vs CA$0.033 in 3Q 2023)

Does Cannara Biotech (CVE:LOVE) Have A Healthy Balance Sheet?

Cannara Biotech Inc.'s (CVE:LOVE) Prospects Need A Boost To Lift Shares

Second quarter 2024 earnings released: CA$0.038 loss per share (vs CA$0.007 loss in 2Q 2023)

Here's Why We Think Cannara Biotech (CVE:LOVE) Might Deserve Your Attention Today

First quarter 2024 earnings released: EPS: CA$0.023 (vs CA$0 in 1Q 2023)

Investor Optimism Abounds Cannara Biotech Inc. (CVE:LOVE) But Growth Is Lacking

Cannara Biotech's (CVE:LOVE) Earnings May Just Be The Starting Point

Full year 2023 earnings released: EPS: CA$0.078 (vs CA$0.026 in FY 2022)

Insufficient new directors

Cannara Biotech Inc., Annual General Meeting, Jan 25, 2024

Is Cannara Biotech (CVE:LOVE) A Risky Investment?

Third quarter 2023 earnings released: EPS: CA$0.03 (vs CA$0.016 in 3Q 2022)

Independent Director recently bought CA$60k worth of stock

Investor sentiment improves as stock rises 24%

Second quarter 2023 earnings released: CA$0.007 loss per share (vs CA$0.013 loss in 2Q 2022)

Cannara Biotech Inc.'s (CVE:LOVE) Business Is Yet to Catch Up With Its Share Price

Here's Why Cannara Biotech (CVE:LOVE) Has A Meaningful Debt Burden

First quarter 2023 earnings released: EPS: CA$0 (vs CA$0.001 loss in 1Q 2022)

Cannara Biotech Inc., Annual General Meeting, Jan 25, 2023

Independent Director recently bought CA$117k worth of stock

Full year 2022 earnings released: EPS: CA$0.003 (vs CA$0.002 loss in FY 2021)

Cannara Biotech Inc. Announces Entry into the British Columbia Market and the Launch of Its First Vape Cartridge and Vape Accessory, Tribal G Mint and Uni Pro Ark

Independent Director recently bought CA$81k worth of stock

Third quarter 2022 earnings released: EPS: CA$0.002 (vs CA$0.002 in 3Q 2021)

Second quarter 2022 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 2Q 2021)

Cannara Biotech's (CVE:LOVE) Earnings Aren't As Good As They Appear

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Cannara Biotech Inc. Announces New Products Launch

Cannara Biotech (CVE:LOVE) Has A Somewhat Strained Balance Sheet

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

High number of new directors

Cannara Biotech Inc. Receives Processing and Cultivation License

Cannara Biotech Inc. Receives Amendment of Its Licence from Health Canada Permitting the Sale of Cannabis 2.0 Products and Prepares for the Launch of Its Hash Product Line in Quebec

Third quarter 2021 earnings released: EPS CA$0.002 (vs CA$0.003 loss in 3Q 2020)

Cannara Biotech Inc. (TSXV:LOVE) completed the acquisition of Quebec Facility of Medican Organic Inc.

Cannara Biotech Inc. (TSXV:LOVE) entered into an agreement to acquire Quebec Facility of Medican Organic Inc. for CAD 32.7 million.

Here's Why Cannara Biotech (CSE:LOVE) Can Afford Some Debt

First quarter 2021 earnings released: CA$0.005 loss per share (vs CA$0.004 loss in 1Q 2020)

Can You Imagine How Cannara Biotech's (CSE:LOVE) Shareholders Feel About The -6.5% Share Price Increase?

Have Insiders Been Buying Cannara Biotech Inc. (CSE:LOVE) Shares?

Full year 2020 earnings released: CA$0.017 loss per share

Cannara Biotech Inc., Annual General Meeting, Jan 25, 2021

Cannara Biotech Inc. Appoints Donald Olds to Board of Directors

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

건강한 기업 발견하기